iBio (IBIO) Set to Announce Earnings on Wednesday

iBio (NASDAQ:IBIO) is projected to post its Q1 2027 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.07) per share and revenue of $0.03 million for the quarter. Parties can check the company’s upcoming Q1 2027 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

iBio (NASDAQ:IBIO) last posted its quarterly earnings results on Friday, August 28th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. On average, analysts expect iBio to post ($0.39) EPS for the current fiscal year and ($0.60) EPS for the next fiscal year.

iBio Price Performance

iBio stock traded up $0.01 during midday trading on Wednesday, reaching $0.83. 29,780 shares of the company traded hands, compared to its average volume of 1,083,023. The business has a 50 day moving average of $1.07 and a two-hundred day moving average of $1.69. The firm has a market capitalization of $53.31 million, a price-to-earnings ratio of -2.44 and a beta of 1.48. iBio has a 12 month low of $0.69 and a 12 month high of $3.82.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on IBIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of iBio in a report on Monday, September 21st. HC Wainwright started coverage on shares of iBio in a report on Thursday, September 17th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Wall Street Zen downgraded shares of iBio from a “hold” rating to a “sell” rating in a research note on Sunday, September 13th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $6.00.

iBio Company Profile

iBio, Inc (NASDAQ: IBIO) is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify and optimize antibody candidates for potential use in cancer and other serious diseases.

iBio’s discovery capabilities are built around proprietary antibody-design and profiling technologies, including platforms intended to improve the speed and quality of therapeutic antibody development.